Actively Recruiting
Phase I Open-Label Study Evaluating Safety and Pharmacokinetics of PGT121.414.LS Alone and with VRC07-523LS in Newborn Infants Exposed to HIV-1
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-11-03
48
Participants Needed
19
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and pharmacokinetics of two powerful, broadly neutralizing anti-HIV monoclonal antibodies called PGT121.414.LS and VRC07-523LS in infants exposed to HIV-1. This open-label, phase I study focuses on administering these antibodies soon after birth to understand their behavior and safety in this vulnerable population. Participants receive one or two subcutaneous doses of PGT121.414.LS alone or combined with VRC07-523LS. The first dose is given at birth based on the infants weight. For some groups, a second dose is administered at Week 12 if the infant is still breastfeeding. The study evaluates the antibody levels and safety through Week 12 for one dose and through Week 24 for two doses. During the study, infants undergo regular safety assessments and blood tests to monitor antibody levels and adverse events. Researchers measure the occurrence of significant side effects, antibody concentrations, and the infants HIV status through Week 96. The study includes monitoring injection site reactions and immune responses to the antibodies, with the total participation lasting up to about two years.
CONDITIONS
Brief Title
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
Research Team
E
Emily Brown
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here